Cerevel Therapeutics Holdings, Inc is a clinical-stage biopharmaceutical company. The Company combines understanding of the biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) receptor pharmacology to discover and develop new therapies. The Company has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson’s disease and substance use disorder. The Company’s pipeline includes Tavapadon, CVL-871, CVL-865, CVL-231 and CVL-936.